Prostate cancer: PSA as an intermediate end point in clinical trials

Nat Rev Urol. 2009 Sep;6(9):473-5. doi: 10.1038/nrurol.2009.130.
No abstract available

Publication types

  • News

MeSH terms

  • Biomarkers / blood
  • Clinical Trials, Phase III as Topic* / methods
  • Endpoint Determination* / methods
  • Humans
  • Male
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / diagnosis

Substances

  • Biomarkers
  • Prostate-Specific Antigen